Gossamer Bio And 2 Other Stocks Under $2 Insiders Are Buying
Gossamer Bio And 2 Other Stocks Under $2 Insiders Are Buying
Gossamer Bio和其他2支股票在$2以下,内部人士正在购买。
The Dow Jones index closed higher by over 250 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
道琼斯指数周一收盘上涨超过250点。当内部人员购买或出售股票时,表明他们对公司前景的信心或担忧。有兴趣投资或交易便士股票的投资者和交易者可以考虑这一因素对其整体投资或交易决策的影响。
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.
以下是几个近期关于低价股的值得关注的内部交易。了解更多,请查看Benzinga内幕交易平台。
Pacific Health Care Organization
太平洋保健组织
- The Trade: Pacific Health Care Organization, Inc. (NASDAQ:PFHO) CEO and President Tom Kubota bought a total of 6,270 shares at an average price of $0.88. To acquire these shares, it cost around $5,543.
- What's Happening: The company reported net income of $176,427 or $0.01 per share for the three months ended June 30, 2023.
- What Pacific Health Care Organization Does: Pacific Health Care Organization Inc is a specialty workers' compensation managed care company.
- 交易:太平洋保健组织股票(NASDAQ:PFHO)的首席执行官兼总裁Tom Kubota以平均价格0.88美元购买了共6270股。购买这些股票需要花费约5543美元。
- 现状:公司报告了2023年6月30日结束的三个月的净利润为176,427美元或每股0.01美元。
- 太平洋保健组织是一家专业的工人赔偿管理保健公司。
System1
System1
- The Trade: System1, Inc. (NYSE:SST) 10% owner Cee Holdings Trust acquired a total of 8,013 shares at an average price of $1.44. To acquire these shares, it cost around $11,575.
- What's Happening: On May 9, System1 posted upbeat first-quarter results.
- What System1 Does: System1 Inc develops technology and data science to operate a responsive acquisition marketing platform.
- 交易:System1, Inc.(NYSE:SST)的10%股东Cee Holdings Trust以平均价格1.44美元收购了共8013股。购买这些股票需要花费约11,575美元。
- 现状:5月9日,System1发布了乐观的第一季度业绩报告。
- System1 Inc开发技术和数据科学,以运营响应式收购营销平台。
Gossamer Bio
Gossamer Bio
- The Trade: Gossamer Bio, Inc. (NASDAQ:GOSS) President and CEO Faheem Hasnain acquired a total of 372,000 shares at an average price of $0.67. The insider spent around $250,282 to buy those shares.
- What's Happening: On June 25, Oppenheimer analyst Andreas Argyrides initiated coverage on Gossamer Bio with an Outperform rating and announced a price target of $9.
- What Gossamer Bio Does: Gossamer Bio Inc is a clinical-stage biopharmaceutical company.
- 交易:Gossamer Bio, Inc.(NASDAQ:GOSS)的总裁兼首席执行官Faheem Hasnain以平均价格0.67美元购买了共372,000股。这位内部人士花费约250,282美元购买这些股票。
- 现状:6月25日,Oppenheimer分析师Andreas Argyrides对Gossamer Bio进行了覆盖,评级为Outperform,并宣布了9美元的目标价。
- Gossamer Bio Inc是一家处于临床阶段的生物制药公司。
Read More: Stocks To Watch On Tuesday: Boeing, FedEx And More
更多阅读:星期二要关注的股票:波音、联邦快递等